预约演示
更新于：2025-02-08
Fluticasone furoate
糠酸氟替卡松
更新于：2025-02-08
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2000-06-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H29F3O6S |
InChIKeyXTULMSXFIHGYFS-VLSRWLAYSA-N |
CAS号397864-44-7 |
关联
221
项与 糠酸氟替卡松 相关的临床试验CTRI/2024/10/075840
A Post-Marketing Active Surveillance Of The FDC Of Fluticasone Furoate 100 or 200 mcg and Vilanterol Trifenatate 25mcg Dry Powder Inhaler Capsules In Patients With Asthma. - none
CTRI/2024/08/073060
A Multi-Centric, Active Post Marketing Surveillance Study to Assess the Safety and Efficacy of Fluticasone Furoate and Vilanterol Powder for Inhalation for the Treatment of Patients with Asthma - NIL
CTRI/2024/06/069178
A Multicenter, Prospective, Open Label, Single arm, Phase IV Study to Assess the Safety and Effectiveness of Vilfuro-G Fixed Dose Combination (Fluticasone Furoate 100 mcg and Glycopyrronium Bromide Ph. Eur. eq. to Glycopyrronium 50 mcg and Vilanterol Trifenatate eq. to Vilanterol 25 mcg) Inhalation powder in Capsule for maintenance treatment of Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease - NIL
100 项与 糠酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 糠酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 糠酸氟替卡松 相关的专利（医药）
登录后查看更多信息
684
项与 糠酸氟替卡松 相关的文献（医药）2025-02-01ADVANCES IN THERAPY
Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Article
作者: Paczkowski, Rosirene ; Laliberté, François ; Schell, Robert C ; Baptist, Alan P ; Klimek, Jacob ; Forero-Schwanhaeuser, Sergio ; Moore, Alison ; Germain, Guillaume ; Noorduyn, Stephen G
INTRODUCTION:
The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US clinical practice. This real-world study assessed asthma-related exacerbations, healthcare resource utilization (HRU), and healthcare costs among a Medicare Advantage-insured population before and after initiation of FF/UMEC/VI in patients with asthma previously treated with an inhaled corticosteroid/long-acting β2-agonist (ICS/LABA).
METHODS:
De-identified data were obtained from the Komodo Health database (01/01/2016-12/31/2023) for adults with asthma who received prior ICS/LABA treatment and had ≥ 12 months of continuous Medicare Advantage coverage both pre- and post-FF/UMEC/VI initiation (index date). Rates of asthma-related exacerbations and HRU were compared using rate ratios (RR) from Poisson regressions. Healthcare costs were calculated per patient per year (PPPY) and compared using mean cost differences from generalized linear models.
RESULTS:
In total, 2598 Medicare Advantage-insured patients who initiated FF/UMEC/VI for asthma were included. The mean ± SD age was 67.9 ± 12.3 years; 75.5% were female. The rate of overall asthma-related exacerbations was 31% lower in the post- versus pre-initiation period (RR 0.69; 95% CI 0.65, 0.73; p < 0.001) and included a 24% lower rate of inpatient/emergency department (IP/ED)-defined exacerbations (RR 0.76; 95% CI 0.68, 0.85; p < 0.001) and a 34% lower rate of systemic corticosteroid (SCS)-defined exacerbations (RR 0.66; 95% CI 0.61, 0.71; p < 0.001). Asthma-related ED visits (RR 0.69; 95% CI 0.60, 0.80; p < 0.001) and asthma-related outpatient (OP) visits (RR 0.77; 95% CI 0.71, 0.84; p < 0.001) were both lower, and the mean reduction in cost was $411 PPPY (95% CI $575, $248; p < 0.001), after FF/UMEC/VI initiation.
CONCLUSIONS:
Initiation of FF/UMEC/VI after ICS/LABA treatment among Medicare Advantage-insured patients with asthma was associated with reduced rates of asthma-related exacerbations, ED and OP visits, and healthcare costs, highlighting the benefits of therapy escalation among this patient population.
2025-02-01JOURNAL OF ASTHMA
Evaluating the timing of triple therapy initiation for the treatment of asthma in Japan: prompt versus delayed
Article
作者: Noorduyn, Stephen G. ; Gelwicks, Steven ; Wood, Robert ; Ito, Risako ; Mukai, Isao ; Payne, Poppy ; Siddiqui, Rad ; Mita, Chifuku ; Oga, Toru ; Requena, Gema ; Wild, Rosie ; Castillo, Catherine M.
OBJECTIVE:
In Japan, the optimal initiation timing and efficacy of single-inhaler triple therapy (SITT) in asthma management remain unexplored. This study investigated SITT initiation timing following an asthma exacerbation, and examined patient demographics and clinical characteristics.
METHODS:
Observational, retrospective cohort study in patients with asthma aged ≥15 years who initiated SITT following their earliest observed asthma exacerbation (February-November 2021), using data from Japanese health insurance claims databases (JMDC and Medical Data Vision [MDV]). The study period ended May 2022 for JMDC and September 2022 for MDV. Descriptive analyses were performed independently by database. Variables evaluated included timing of SITT initiation post exacerbation (prompt, delayed and late, ≤30, 31-180 and >180 days post index, respectively), patient demographics, clinical characteristics, and pre-index treatment.
RESULTS:
Of patients in the JMDC and MDV databases, most initiated SITT promptly after an asthma exacerbation, 60.8% (n = 951/1565) and 44.4% (n = 241/543), respectively. Delayed initiation occurred in 22.6% (n = 354/1565) and 26.3% (n = 143/543) of patients, and late initiation occurred in 16.6% (n = 260/1565) and 29.3% (n = 159/543), respectively. Most patients were indexed on a moderate asthma-related exacerbation, 97.1% (n = 1519/1565) and 68.7% (n = 373/543), respectively.
CONCLUSION:
Most patients with asthma initiated SITT promptly following a moderate exacerbation, with delayed and late initiation more common among patients with complex clinical profiles. The findings underscore the necessity for future research to examine the interaction between patient characteristics, clinical outcomes, and the timing of SITT initiation to optimize treatment strategies, as clinical practice may vary by exacerbation severity.
2025-02-01ADVANCES IN THERAPY
Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease
Article
作者: Boudreau, Julien ; Mannino, David ; Noorduyn, Stephen G ; Laliberté, François ; Weng, Stephen ; Tardif-Samson, Anabelle ; Forero-Schwanhaeuser, Sergio ; Germain, Guillaume ; Gravelle, Patrick ; Paczkowski, Rosirene ; Compton, Chris H
INTRODUCTION:
Chronic obstructive pulmonary disease (COPD) is associated with exacerbations which can reduce quality of life and increase mortality. Single-inhaler triple therapy (SITT) is recommended for maintenance treatment of COPD among patients experiencing exacerbations despite dual-therapy use. This real-world comparative effectiveness study compared the impact of SITTs, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), and budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), on COPD exacerbations and mortality.
METHODS:
Medicare Fee-for-Service (FFS) patients with COPD initiated on FF/UMEC/VI or BUD/GLY/FORM were identified from the Komodo Research healthcare claims dataset (01/01/2016-12/31/2023). Overlap weighting based on high-dimensional propensity scores evaluated from patient characteristics was used to adjust for baseline confounding. Primary outcome was annualized rate of moderate-severe COPD exacerbations (per patient-year; PPY) compared using rate ratios (RRs) with 95% confidence intervals (CIs) from weighted Poisson regression models. Secondary and exploratory outcomes were risk of moderate-severe COPD exacerbations and all-cause mortality, respectively, evaluated using Kaplan-Meier analysis and hazard ratios (HR) with 95% CIs from Cox proportional hazard models. A secondary analysis was conducted among a mutually exclusive population with Medicare Advantage, Medicaid, or commercial insurance.
RESULTS:
Overall, 32,312 FF/UMEC/VI and 12,230 BUD/GLY/FORM Medicare FFS patients were included. After weighting, median follow-up was 9 months. Compared with BUD/GLY/FORM, FF/UMEC/VI users had a 12% lower rate of annualized moderate-severe COPD exacerbations [0.80 and 0.91 PPY; RR (95% CI): 0.88 (0.85-0.92); P < 0.001] and a 10% lower risk of moderate-severe exacerbations at 12 months post-initiation [HR (95% CI): 0.90 (0.87-0.93); P < 0.001], driven by moderate exacerbations. FF/UMEC/VI compared with BUD/GLY/FORM users had 11% lower risk of all-cause mortality at 12 months post-initiation [5.6% vs. 6.4%; HR (95% CI): 0.89 (0.80-0.98); P = 0.020]. Results were consistent among patients with Medicare Advantage, Medicaid, or commercial insurance.
CONCLUSIONS:
In this real-world comparative effectiveness study, FF/UMEC/VI was associated with significantly lower rate and risk of COPD exacerbations than BUD/GLY/FORM.
100 项与 糠酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 美国 | 2014-08-20 | |
| 慢性阻塞性肺疾病 | 澳大利亚 | 2014-04-17 | |
| 常年性变应性鼻炎 | 加拿大 | 2007-10-22 | |
| 季节性过敏性鼻炎 | 加拿大 | 2007-10-22 | |
| 过敏性鼻炎 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管疾病 | 临床3期 | 美国 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 中国 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 日本 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 阿根廷 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 澳大利亚 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 奥地利 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 白俄罗斯 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 比利时 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 波斯尼亚和黑塞哥维那 | 2011-01-25 | |
| 心血管疾病 | 临床3期 | 保加利亚 | 2011-01-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 常年性变应性鼻炎 维持 | 87 | Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily) | 夢衊選顧夢壓鹽齋壓繭(觸憲繭願壓遞願構構糧): mean difference = 1.26 (95% CI, 0.59 ~ 1.93), P-Value = <0.001 | 积极 | 2024-02-23 | |
Fluticasone furoate (FF 55 μg each nostril once daily) | |||||||
N/A | - | - | 顧蓋鑰選顧糧鹹衊積積(遞繭簾鬱簾艱淵觸壓夢) = Similar proportions of participants experienced ≥1 on-treatment adverse event (AE) in both populations (5-17 year-olds: n=181/454 [40%] receiving FF/VI versus n=163/448 [36%] receiving FF; 5-11 year-olds: n=133/337 [39%] receiving FF/VI versus n=122/336 [36%] receiving FF) 淵襯獵蓋願獵鬱淵鹽築 (範積顧顧願遞構製廠衊 ) | - | 2023-05-21 | ||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 衊繭繭醖繭構衊鬱獵選(淵築蓋廠簾壓廠壓憲簾) = 獵淵網餘願遞觸艱淵糧 膚淵積淵鹽鏇艱鹽範獵 (網餘範壓鬱餘顧壓襯鬱, 襯膚齋簾選襯蓋觸餘齋 ~ 廠繭淵製艱範糧網構壓) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 衊繭繭醖繭構衊鬱獵選(淵築蓋廠簾壓廠壓憲簾) = 遞簾鬱襯簾範壓糧鏇壓 膚淵積淵鹽鏇艱鹽範獵 (網餘範壓鬱餘顧壓襯鬱, 觸積範鑰憲範構鹽構顧 ~ 遞鹽願顧鬱簾鬱簾鹽鹹) 更多 | ||||||
临床3期 | 1,407 | (Arm C - Fluticasone) | 夢網構膚繭觸鏇醖鹹廠(憲積醖鏇繭衊鹹範壓壓) = 膚艱繭衊範選簾構壓夢 鹽蓋網鹹簾鹹積築簾窪 (襯餘蓋簾壓鹹襯構製觸, 鹽壓醖簾製築鹹襯構構 ~ 糧艱鬱壓夢醖範鬱膚鹽) 更多 | - | 2023-04-12 | ||
Placebo (Arm C - Placebo) | 夢網構膚繭觸鏇醖鹹廠(憲積醖鏇繭衊鹹範壓壓) = 壓網遞構憲願醖獵淵餘 鹽蓋網鹹簾鹹積築簾窪 (襯餘蓋簾壓鹹襯構製觸, 範鏇積衊鏇鏇範願獵選 ~ 鏇鹹鏇膚糧範鬱製鹽餘) 更多 | ||||||
临床4期 | 477 | Placebo+Montelukast | 壓壓構築憲糧製構鹽壓(憲衊壓顧鏇遞構簾鬱壓) = 鏇廠淵顧餘選繭觸醖鹹 鹹醖餘膚鏇選廠鹽鏇蓋 (鏇願窪蓋蓋願壓選製願, 鑰膚繭遞膚壓鏇繭糧構 ~ 窪鬱窪鹽範廠衊壓艱醖) 更多 | - | 2022-01-04 | ||
临床3期 | 211 | (Nasal Steroids) | 艱淵膚築選網襯齋鹹鬱(糧築積繭窪觸願繭鹹齋) = 鹽觸淵範願繭鹹蓋窪製 鹹鑰憲膚範艱鬱鏇廠蓋 (糧範衊簾願積遞製遞齋, 齋襯觸鹽壓餘鹽廠夢鹹 ~ 衊願淵廠鹽鹹範觸網簾) 更多 | - | 2021-03-10 | ||
Placebo (Placebo) | 艱淵膚築選網襯齋鹹鬱(糧築積繭窪觸願繭鹹齋) = 遞網齋簾夢獵夢膚鹽選 鹹鑰憲膚範艱鬱鏇廠蓋 (糧範衊簾願積遞製遞齋, 簾鹹衊鹽遞膚鑰艱鑰構 ~ 窪顧獵窪鑰構鑰積鹽願) 更多 | ||||||
临床3期 | - | 餘獵蓋窪鹹鹹襯淵淵獵(糧淵網餘築繭製鬱製遞): hazard ratio = 0.89 (95% CI, 0.67 ~ 1.16), P-Value = 0.387 | 积极 | 2020-06-15 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
临床2期 | 54 | Fluticasone furoate (FF) | 簾簾觸獵網鑰鑰衊製膚(願築鬱鬱觸網醖廠積選) = 蓋製顧憲艱願繭繭簾憲 遞鏇構夢選淵糧夢蓋齋 (襯範願築襯鏇選網壓鑰, 18 ~ 129) | - | 2019-09-28 | ||
Fluticasone propionate (FP) | 簾簾觸獵網鑰鑰衊製膚(願築鬱鬱觸網醖廠積選) = 餘獵簾顧築網壓廠鑰餘 遞鏇構夢選淵糧夢蓋齋 (襯範願築襯鏇選網壓鑰, 448 ~ 2610) | ||||||
临床1期 | - | 16 | 積鏇襯齋構夢淵願網鬱(鑰齋繭簾獵糧齋餘繭構) = 憲夢積衊齋醖網構餘範 鏇鏇鏇觸廠網壓鑰醖願 (築選淵範襯構構鹹顧遞 ) 更多 | - | 2019-08-01 | ||
临床1期 | - | 48 | BAT/FF | 齋構願齋獵願壓淵蓋簾(淵憲襯網遞鏇餘遞窪醖): P-Value = 0.79 更多 | - | 2019-02-01 | |
FF |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用